This early phase I trial tests the use of a radioactive tracer (a drug that is visible during an imaging test) known as 18F-FMAU, for imaging with positron emission tomography/computed tomography (PET/CT) in patients with brain cancer or cancer that has spread to the brain (brain metastases). A PET/CT scan is an imaging test that uses a small amount of radioactive tracer (given through the vein) to take detailed pictures of areas inside the body where the tracer is taken up. 18F-FMAU may also help find the cancer and how far the disease has spread. Magnetic resonance imaging (MRI) is a type of imaging test used to diagnose brain tumors. 18F-FMAU PET/CT in addition to MRI may make the finding and diagnosing of brain tumor easier.

开始日期2021-02-15

申办/合作机构

University of Southern California

[+1]

NCT02809690 / Terminated临床1期IIT

Pilot Feasibility Study of 18F-FMAU PET for Diagnosing and Characterizing Prostate Cancer

This pilot clinical trial studies how well fluorine F 18 d-FMAU (18F-FMAU) positron emission tomography (PET)/computed tomography (CT) works in diagnosing and characterizing prostate cancer. A PET/CT scan is an imaging test that uses a small amount of radioactive tracer that is given through the vein to take detailed pictures of areas inside the body where the tracer is taken up. Radiotracers such as 18F-FMAU may help to find the cancer and see how far the disease has spread.

开始日期2016-09-12

申办/合作机构

University of Southern California

[+2]

100 项与 18F-FMAU 相关的临床结果

登录后查看更多信息

100 项与 18F-FMAU 相关的转化医学

登录后查看更多信息

100 项与 18F-FMAU 相关的专利（医药）

登录后查看更多信息

项与 18F-FMAU 相关的文献（医药）

2017-02-01·Molecular Imaging and Biology3区 · 医学

Comparative Analysis of Human Nucleoside Kinase-Based Reporter Systems for PET Imaging

3区 · 医学

Article

作者: Sumzin, Nikita ; Ponomarev, Vladimir ; Likar, Yury ; Moroz, Maxim A ; Zhang, Hanwen ; Collins, Jeffrey ; Shenker, Larissa ; Lee, Jason T ; Zurita, Juan ; Lobo, Jose ; van Dam, R Michael

PURPOSERadionuclide-based reporter gene imaging has the sensitivity to monitor gene- and cell-based therapies in human subjects. Potential immunogenicity of current viral transgenes warrants development of human-based reporter systems. We compared human nucleoside kinase reporters to a panel of nucleoside analogs of FEAU, FMAU, and FIAU, including the first in vivo assessment of L-[¹⁸F]FEAU.PROCEDURESHuman isogenic U87 cell lines were transduced to express different human reporter genes including dCK-R104M/D133A (dCKDM), dCK-R104Q/D133N (dCKep16A), dCK-A100V/R104M/D133A (dCK3M), and TK2-N93D/L109F (TK2DM), and wild-type dCK (dCK) and herpes simplex virus type-1 (HSVTK) reporter gene as references. In vitro cell uptake assays were performed with [¹⁸F]FEAU, L-[¹⁸F]FEAU, [¹⁴C]FMAU, L-[¹⁸F]FMAU, and [¹²⁴I]FIAU. Micro-positron emission tomography/X-ray computed tomography imaging of xenograft-bearing nu/nu mice was conducted with [¹⁸F]FEAU, L-[¹⁸F]FEAU, L-[¹⁸F]FMAU, and [¹²⁴I]FIAU on consecutive days. A cell viability assay was also performed to assess sensitivities to gemcitabine and bromovinyldeoxyuridine (BVdU).RESULTSIn vitro, dCKep16A and dCKDM with [¹⁸F]FEAU exhibited the highest sensitivity and selectivity of the human reporters, second only to HSVTK/[¹⁸F]FEAU. L-[¹⁸F]FEAU biodistribution in mice was on par with [¹⁸F]FEAU and L-[¹⁸F]FMAU. L-[¹⁸F]FMAU uptake in isogenic xenografts was highest for all human reporter genes. However, [¹⁸F]FEAU was the most selective of the short half-life reporter probes due to its minimal recognition by human dCK and relative sensitivity, whereas [¹²⁴I]FIAU permitted imaging at a later time point, improving signal-to-background ratio. Of the human reporter genes, dCKep16A consistently outperformed the other tested reporters. Reporter genes of interest increased potency to the nucleoside analog prodrugs gemcitabine and BVdU.CONCLUSIONSWe demonstrate that human nucleoside kinase reporter systems vary significantly in their sensitivity and selectivity for in vivo imaging. The sufficiently high signal-to-background ratios and enhanced suicide gene potential support clinical translation.

100 项与 18F-FMAU 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB14913

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
脑转移瘤	临床1期	美国	National Cancer Institute	2021-02-15
结肠癌	临床1期	美国	National Cancer Institute	2021-02-15
胶质瘤	临床1期	美国	National Cancer Institute	2021-02-15
皮肤黑色素瘤	临床1期	美国	National Cancer Institute	2021-02-15
转移性乳腺癌	临床1期	美国	National Cancer Institute	2021-02-15
转移性结直肠癌	临床1期	美国	National Cancer Institute	2021-02-15
转移性肺癌	临床1期	美国	National Cancer Institute	2021-02-15
转移性黑色素瘤	临床1期	美国	National Cancer Institute	2021-02-15
肾细胞癌	临床1期	美国	National Cancer Institute	2021-02-15
前列腺癌	临床1期	-	The University of Texas at Austin	-